Drugs / IMP761
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06637865 | Jul 2024 → Aug 2026 overdue | — | Immutep S.A.S. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-06-04 | Immutep S.A.S. | Results Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 immutep.com ↗
Initial clinical findings showed significant and clinically relevant pharmacodynamic activity, including reduction of local inflammatory responses and attenuated T-cell activity compared to placebo across cohorts ranging from 0.9 mg/kg to 7 mg/kg, with 7 mg/kg being statistically significantly better in terms of skin blood perfusion compared to placebo (p = 0.029). |
| 2026-03-19 | Immutep S.A.S. | Results Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases immutep.com ↗
IMP761 was well tolerated across all dose levels, and no safety concerns or dose-limiting toxicities were observed to date. |
| 2025-12-22 | Immutep S.A.S. | Results Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study immutep.com ↗
The single-ascending dose escalation portion of the trial has successfully completed the 2.5 and 7 mg / kg dosing levels of IMP761 with continued positive safety and efficacy data. |
| 2025-06-23 | Immutep S.A.S. | Results Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases immutep.com ↗
Additionally, pharmacodynamic data at this dosing level show that the inhibition of T cell infiltration in the skin at day 10 following a neoantigen rechallenge has already reached 80%. |
| 2024-12-16 | Immutep S.A.S. | Results Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 immutep.com ↗
Through the first three of five single ascending dose cohorts in healthy participants, there have been no treatment related adverse events. |
| 2024-07-17 | Immutep S.A.S. | Regulatory Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases immutep.com ↗
today announces it has received regulatory clearance from the ethics and competent authority in the Netherlands to initiate the first-in-human Phase I study of IMP761. |
| 2022-07-05 | Immutep S.A.S. | Regulatory Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3 immutep.com ↗
Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce the grant of a new patent (number 7074341) entitled “Anti-LAG-3 Antibodies” by the Japanese Patent Office. |
| 2019-03-06 | Immutep S.A.S. | Results Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation immutep.com ↗ |
| 2018-09-03 | Immutep S.A.S. | Results Progress Towards Clinical Development of IMP761 – A LAG-3 Agonist Antibody immutep.com ↗
This signals the advancement of IMP761 towards Good Manufacturing Practice (GMP) manufacturing and clinical development for the treatment of autoimmune diseases by Immutep and follows new and encouraging preclinical results that demonstrate the immunosuppressive activity of IMP761 in vivo . |
All press releases naming this drug 19 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP761 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06637865 ↗ |
| Action | Activate | “LAG-3 Agonist Antibody” NCT06637865 ↗ |
| Target | LAG3 | “LAG-3 Agonist Antibody” NCT06637865 ↗ |